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Atrial natriuretic factor inhibits hypertonic saline-mediated
decreases in renal hemodynamics
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Atrial natriuretic factor inhibits hypertonic saline-mediated decreases
in renal hemodynamics. The present study in the anesthetized dogs was
designed to test the hypothesis that atrial natriuretic factor (ANF)
attenuates whole kidney tubuloglomerular feedback (TGF) mediated
decreases in renal blood flow (RBF) and glomerular filtration rate (GFR)
produced by hypertonic saline (HS). Secondly, as adenosine (AD) has
been implicated as a metabolic mediator of TGF, we also hypothesized
that ANF would antagonize the renal actions of AD. To test this
hypothesis, RBF and GFR were assessed in response to hypertonic
saline (HS, 16%, i.r.) or adenosine (AD, 0.1 mol/min, i.r.) in the
presence and absence of exogenous ANF (100 ng/kglmin, i.r.). ANF
attenuated HS-mediated reductions in GFR (HS, —39.6 9.8 mI/mm
vs. HS + ANF, —14.3 4.5 mI/mm, P < 0.05) and in RBF (HS, —143
35 mI/mm vs. HS + ANF, —5 22 mI/mm, P < 0.05). GFR was
reduced by AD (—9.2 3.0 mI/mm, P < 0.05), but maintained by AD
+ ANF (—0.4 2.0 mI/mm, NS). A transient adenosine-mediated
vasoconstnction was attenuated by ANF (AD, —54.5 3.6 mI/mm vs.
AD + ANF, —3.7 3.1 mI/mm, P < 0.005). We conclude that ANF at
pharmacologic concentrations attenuates at the whole kidney level
hypertonic saline and adenosine-mediated reductions in RBF and GFR.
Tubuloglomerular feedback is a renal blood flow autoregula-
tory mechanism which participates in the control of glomerular
filtration rate (GFR) [1—3]. Activation of TGF may occur in
response to an increase in delivery of sodium and chloride to
the macula densa. Activation results in a renal hemodynamic
response characterized by a decrease in renal blood flow
secondary to an increase in afferent arteriolar resistance and a
subsequent decrease in GFR secondary to a decrease in gb-
merular hydrostatic pressure. The sensitivity of TGF in re-
sponse to increases in solute load to the macula densa is
decreased in acute and chronic states of intravascular volume
expansion. This is in contrast to enhanced sensitivity in states
of volume depletion.
Recent studies have suggested a modulating role for pharma-
cologic concentrations of atrial natriuretic factor (ANF) in the
control of TGF. Huang and Cogan have reported in microper-
fusion studies that pharmacologic concentrations of ANF may
attenuate TGF-mediated decreases in single nephron glomeru-
lar filtration (SNGFR) [4]. Such studies confirm earlier reports
of Briggs and Schnermann in which crude atrial extracts
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blunted TGF-mediated decreases in SNGFR [5,6]. More recent
studies by Polbock and Arendshort suggest that these earlier
studies employing artificial tubular fluid for microperfusion
overestimated the inhibitory action of ANF upon TGF [7]. To
date, therefore, the significance of these microperfusion studies
upon the modulating action of pharmacologic concentrations of
ANF upon whole kidney TGF-mediated control of renal blood
flow (RBF) and GFR are unknown. Furthermore, potential
mechanism(s) by which ANF may modulate the renal hemody-
namic response to TGF activation has also not been investi-
gated.
The objective of the present investigation was twofold. The
first objective was to determine if ANF, infused into the renal
artery at pharmacologic concentrations in anesthetized dogs,
attenuates the RBF and GFR reductions to renal artery infusion
of hypertonic saline. Although micropuncture was not em-
ployed in the current study, previous investigators have dem-
onstrated that hypertonic saline may serve as a stimulus to TGF
at the whole kidney level to decrease RBF and GFR [6, 8]. The
second objective of the present study was to determine if renal
artery infusion of ANF attenuates the transient renal vasocon-
striction and the more prolonged decrease in GFR to renal
artery infusion of adenosine, a putative metabolic mediator of
TGF [9]. Thus, these studies were designed to test the hypoth-
esis that pharmacologic concentrations of exogenous ANF
attenuates HS-mediated decreases in renal blood flow and
glomerular filtration rate as well as the renal action of adeno-
sine.
Methods
Studies were performed on male mongrel dogs weighing 16 to
28 kg. Experiments were performed on two groups of dogs:
Group 1 (N = 12) consisted of normal dogs receiving intrarenal
hypertonic saline (HS), and Group 2 (N = 12) consisted of dogs
receiving intrarenal adenosine (AD).
On the day of the acute experiments all dogs were anesthe-
tized with pentobarbital (30 mg/kg, i.v.), and supplemented with
small amounts as necessary. After endotracheal intubation.
animals were ventilated using a Harvard respirator. Both fern-
oral arteries and one femoral vein were cannulated and PE 240
polyethylene tubing inserted. One femoral artery was cannu-
bated to permit blood sampling for determining plasma levels of
inulin and electrolytes. To avoid perturbation of renal hernody-
namics during blood sampling, care was taken to place the tip of
this catheter distal to the renal artery, advancing it only 5 to 8
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cm proximal to the inguinal ligament. The other femoral artery
was cannulated with the catheter tip placed in the thoracic aorta
for continuous arterial blood pressure measurements. A femo-
ral vein was cannulated for infusion of inulin to maintain a
plasma level of 50 nglml. The left kidney was exposed through
a retroperitoneal flank incision. In the event two renal arteries
supplied this kidney, the incision was closed to prevent evap-
orative fluid loss, and the right kidney was exposed through a
separate flank incision. The corresponding ureter was then
cannulated with PE 240 polyethylene tubing for timed urine
collections. An electromagnetic flow probe (Carolina, King,
North Carolina, USA) was placed around the renal artery and
connected to a flow meter for continuous measurement of renal
blood flow. Renal blood flow and arterial blood pressure were
simultaneously recorded on a Gould model 2200 strip-chart
recorder. Two curved 23 gauge needles attached to PE 50
polyethylene tubing were inserted into the renal artery proximal
to the flow probe for administration of the following solutions
depending on the protocol: hypertonic saline, adenosine, atrial
natriuretic factor (ANF), or vehicle. Patency was maintained in
these catheters by infusion of isotonic saline (protocol 1) or
isotonic dextrose (protocol 2) at a rate of 0.1 mi/mm. After
surgical preparation, the animals were allowed to stabilize for
60 minutes prior to initiating the protocols. Each protocol
consisted of four observation periods: 1) baseline, 2) control, 3)
HS or AD infusion, and 4) recovery.
Experimental
Protocol 1: Effect of airial natriuretic factor on hypertonic
saline-induced reductions in renal hemodynamics. Following
stabilization, two 15-minute baseline clearances which were
meaned for data analysis, were obtained for the measurement of
renal hemodynamics. Saline vehicle (HS + VEH, N = 6) or
ANF (HS + ANF, 100 nglkglmin, N = 6, Penninsula Labora-
tories, Belmont, California, USA) was then administered di-
rectly into the renal artery at 1.2 mI/mm. The atrial peptide used
was the 28 amino acid ah-ANF. Fifteen minutes after initiation
of this infusion, a 15-minute control clearance was obtained,
documenting any changes due to VEH or ANF. The infusion of
VEH or ANF was then continued and a 10-minute hypertonic
saline infusion (16.2% i.r.) was initiated. The infusion rate of
HS was adjusted relative to changes in renal blood flow as
previously described by Heidemann et a! using a Harvard 906
variable rate infusion pump to maintain a constant estimated 30
mEq/liter increase in plasma sodium concentration [10]. After
five minutes of HS infusion, with the stabilization of urine flow,
a five minute clearance was obtained. HS was then discontin-
ued and 15 minutes later, ANF or VEH was stopped. After an
additional 15 minutes, a 15-minute recovery clearance was
obtained. All solutions for this protocol were made in isotonic
saline.
Protocol 2: Effect of atrial natriuretic factor on adenosine-
mediated reductions in renal hemodynamics. This protocol
substituted adenosine for hypertonic saline. Because the renal
response to adenosine is more pronounced in volume depleted
animals, these experiments were performed on animals that had
previously been given a single injection of furosemide (40 mg
i.m.) and then maintained on a diet of 447 gm of HD chow
(Hills, Topeka, Kansas, USA) with 5 mEq sodium administered
daily for at least five days prior to the acute experiment. As a
result, urine flows were diminished and longer clearance peri-
ods were required to ensure accurate GFR determination.
Additionally, isotonic dextrose (5.5 mg/dl) was substituted for
isotonic saline as the vehicle in all solutions to prevent sodium
repletion. As in protocol 1, following stabilization, two baseline
clearances were obtained except each was 30 minutes in dura-
tion. Following baseline clearances, dextrose vehicle (AD +
DEX, N 6) or ANF (AD + ANF, N 6) was administered at
1.2 mi/mm (i.r.). Fifteen minutes after initiation of this infusion,
a control clearance was obtained documenting any changes due
to ANF or DEX. The infusion of vehicle or ANF was then
continued as adenosine (0.1 molIliter) was infused at 1.0
mi/mm (i.r.) for 20 minutes, a dose previously documented to
result in reproducible reduction in GFR [11]. After 10 minutes
of AD infusion, a 10 minute clearance was obtained. AD was
then discontinued and 10 minutes later, ANF or DEX was
stopped. After an additional 10 minutes, a 10-minute recovery
clearance was obtained. All solutions used in this protocol were
made in dextrose.
Glomerular filtration rate was measured by the clearance of
inulin. Inulin concentrations were measured by the anthrone
method [121. Sodium and potassium were measured using
ion-selective electrodes (Beckman E2A analyzer, Beckman
Instruments, Fullerton, California, USA).
All data from the clearances in baseline, control, hypertonic
saline, adenosine, and recovery periods were averaged and are
expressed as mean SE. The data were analyzed using Dun-
nett's paired t-test for simultaneous and multiple comparisons.
Results
Renal hemodynamic and excretory function were measured
during baseline, control (vehicle or ANF infusion), HS or AD
infusion, and recovery periods, and are summarized in Tables 1
and 2.
Protocol I
Hypertonic saline alone (HS + VEH. Compared to baseline
and control periods, dogs receiving HS alone demonstrated
marked reductions in GFR and RBF. Urine flow rate and
urinary sodium excretion tended to increase, although these
changes were not significant. Urine osmolality decreased and
mean arterial blood pressure remained stable.
Hypertonic saline with ANF (HS + ANF,)
Compared to baseline, ANF resulted in significant increases
in GFR and no change in RBF. HS decreased GFR but this
reduction in GFR was significantly less than when hypertonic
saline was infused with vehicle (Fig. 1). The changes in RBF in
this group were not significant, although a transient vasodilation
was observed when the ANF infusion was initiated, consistent
with previous observations from this laboratory [131, and there
was a tendency for RBF to increase during the hypertonic saline
infusion. Representative RBF responses of dogs in each of the
two groups receiving hypertonic saline are depicted in Figure 2.
MAP was unchanged between periods in this group. Sodium
excretion and urine flow increased in the control and HS
infusions periods. U0sm was decreased with the ANF infusion.
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Table 1. Effect of hypertonic saline on renal hemodynamic and excretory function in the absence or presence of ANF
Hypertonic
Baseline Control saline infusion Recovery
HS + VEH (N = 6)
MAP mm Hg
GFR mI/mm
142 6
42.5 1.7
142 3
49.6 7.2
152 4
10.0 54a.b
148 6
31.1 8.3
RBF mI/mm 253 31 280 43 137 43a.b 238 51
V mI/mm 0.21 .1 0.29 .12 2.0 .8 0.3 .1
UNaV p.Eq/min
Uom mOsm/liter
29.3 16.0
1439 166
42.9 20.8
1461 188
638.8 220.1
555 30a,b
92.5 19.9
829 200
HS + ANF (N = 6)
MAP mm Hg 136 7 135 8 135 8 143 4
GFR mi/mm 30.7 2.3 57.6 6.6a 43.3 3.7' 441 5.3
RBF mI/mm 258 42 280 45 275 57 268 16
V mi/mm 0.3 .1 4.3 •9 12.4 23a,b 0.8 .2
UNaV pEq/min 39.7 11.8 557.1 103.9a 2365.4 4081a,b 151.9 339k
Uosm mOsm/liter 971 204 332 17 396 13 651 41
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular filtration rate; RBF, renal blood flow; ', urine flow; UNV, urinary sodium
excretion; Usm, urinary osmolality. a P < 0.05 vs. baselineb p < 0.05 vs. control
Table 2. Effect of intrarenal adenosine on renal hemodynamic and excreto ry function in the absence or presencc of ANF
Baseline Control Adenosine infusion Recovery
AD + VEH (N = 6)
MAPmmHg 134±6 138±6 139±6 140±5
GFR mi/mm 25.0 3.0 28.3 2.1 19.1 2.9a 23.2 3.9
RBF mI/mm 154 17 153 18 160 18 155 19
V mi/mm 0.1 .01 0.3 .l 0.2 .1 0.3 .2
UNaV pEq/min 4.5 1.3 6.2 2.2 3.9 1.3 4.8 1.5
Uosm mOsm/liter 1159 223 734 143 732 219 672 134
AD + ANF (N = 6)
MAP mm Hg 138 7 127 8 126 7 127 8
GFR mi/mm 28.9 2.6 42.6 49a 42.2 39a 40.5 5.7
RBF mI/mm 212 21 213 19 257 26' 223 22
'' mI/mm 0.1 .01 2.1 •4 1.3 .2 0.4 .l
UNaV p.Eq/min 4.6 .7 133.7 345a 98.4 27.4a 19.4 49a
Uosm mQsm/Iiter 1204.8 68.3 325.3 52.8a 380.8 39.8a 537.3 70.1
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular filtration rate; RBF, renal blood flow; T, urine flow; UNaV, urinary sodium
excretion; Uosm, urinary osmolality.aP < .05 vs. baselineb p < 0.05 vs. control
Protocol 2
Adenosine alone (AD + DEX). Compared to baseline and
control, AD alone reduced GFR with a transient decrease in
RBF. This transient change in RBF is depicted in a repre-
sentative tracing from one dog (Fig. 3). RBF tended to increase
above control values after three to five minutes of AD infusion.
Urine flow increased. Urine osmolality tended to decrease after
baseline but was significantly decreased only during AD infu-
sion. Mean arterial pressure and urinary sodium excretion did
not change during any of the periods.
Adenosine with ANF (AD + ANF). ANF produced an
increase in GFR from baseline values that persisted throughout
the experiment. AD decreased GFR but this reduction was
significantly less than when AD was infused without ANF (Fig.
1). RBF remained stable from baseline to control periods. With
the AD infusion, ANF significantly attenuated the decrease in
RBF (AD —54.5 3.6 vs. AD + ANF, —3.7 8.1 mllmin, P <
0.05) followed by a sustained increase (Fig. 3). Arterial pressure
and urine osmolality decreased with ANF infusion and re-
mained depressed throughout the experiment. Urine flow and
sodium excretion increased with ANF and remained elevated
throughout the experiment.
Discussion
The present studies demonstrate that administration of hy-
pertonic saline (HS) into the renal artery results in a transient
renal vasodilatation followed by a decrease in renal blood flow
(RBF). This renal vasoconstrictor response was associated with
a reversible decrease in glomerular filtration rate (GFR). Ad-
ministration of pharmacologic concentrations of ANF during
infusion of HS attenuated both the renal vasoconstriction and
decrease in GFR. The present studies also demonstrate that
infusion into the renal artery of adenosine (AD), which has been
postulated to be a possible metabolic mediator of TGF [9, 11,
14], results in a transient renal vasoconstriction followed by a
decrease in GFR which is also attenuated by ANF. These
studies thus demonstrate that pharmacologic concentrations of
ANF block HS- and AD-mediated decreases in RBF and GFR
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and support a modulating role for exogenous ANF in the TGF
phenomenon as activated by hypertonic saline.
Aortic administration of HS above the renal arteries or
increasing rates of loop perfusion have resulted in reductions in
single nephron glomerular filtration rate and/or stop flow pres-
sure as determined by cortical micropuncture studies [3, 6].
Renal arterial administration of HS in the dog have extended
this phenomenon to the whole kidney and documented parallel
reductions in RBF and GFR [8, 10]. Such investigations have
supported the concept of a TGF autoregulatory phenomenon
which participates in the regulation of GFR in response to
increased delivery of sodium chloride to the macula densa.
States of acute and chronic intravascular volume expansion
decrease TGF sensitivity in contrast to an enhanced sensitivity
in states of acute or chronic volume contraction.
While redundant factors involved with volume homeostasis
have been implicated in the modulation of TGF sensitivity,
ANF has emerged as a physiologic regulator of cardiorenal
homeostasis which could serve as a modulator of TGF sensi-
tivity [15, 16]. Briggs et al reported that high concentrations of
crude atrial extract attenuated TGF-mediated reduction in stop
flow pressure [5]. More recently, Huang and Cogan have
demonstrated with loop microperfusion that maximal TGF-
mediated reductions in SNGFR are also attenuated by high-
dose ANF [4]. While these studies support at the single nephron
level a role for ANF in attenuating TGF-mediated reductions in
SNGFR and/or SFP during high rate single nephron infusion of
artificial tubular fluid, the ability of ANF to attenuate whole
kidney GFR and specifically TGF-mediated reductions in RBF
has not been investigated. The present studies thus confirm and
extend to the whole kidney level these previous investigations
and demonstrate that pharmacologic concentrations of ANF
inhibit both HS- and AD-induced reductions in RBF and GFR
at the level of the whole kidney.
The mechanism(s) by which ANF inhibits the HS-mediated
decreases in RBF and GFR could be upon inhibition of either
the sensor or the effector limb of the TGF phenomenon. High
concentrations of intraluminal ANF could desensitize sensing
mechanisms at the site of the macula densa. An alternative
mechanism may be that intrarenal ANF serves to inhibit the
effector limb by inhibiting afferent arteriolar vasoconstriction,
thereby preserving glomerular hydrostatic pressure, GFR, and
renal blood flow.
Previous studies have supported a role for adenosine as a
potential metabolic mediator of TGF [9, 11, 141. Such studies
have speculated that increases in solute delivery to the macula
densa with increased solute transport results in increases in
adenosine concentration in the tissue adjacent to the afferent
vessels. An increase in interstitial adenosine alone or in asso-
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Fig. 3. Representative renal blood flow (RBF) tracing during continu-
ous administration of adenosine (AD) without, A, or with, B, infusion of
atrialnatriuretic factor (ANF) into the renal artery.TiI__ P<0.01
AD AD+ANF
Fig. 1. Absolute decreases in glomerular filtration rate (GFR) in re-
sponse to hypertonic saline (HS), A and adenosine (AD), B, in the
presence and absence of infusion of atrial natriuretic factor (ANF) into
the renal artery.
HS (16.2%)
0 10mm
FIg. 2. Representative renal blood flow (RBF) tracing during continu-
ous administration of hypertonic saline (HS) without, A, or with, B,
infusion of atrial natriuretic factor (ANF) into the renal artery.
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ciation with other intrarenal vasoconstrictors such as angioten-
sin II could mediate increases in the resistance of the afferent
arteriole [17]. Studies have also supported an action of adeno-
sine to induce mesangial contraction via a specific A1-type
receptor, thus decreasing the ultrafiltration coefficient, K [14].
Our studies demonstrate that ANF antagonizes the hemody-
namic action of adenosine to decrease RBF and GFR. While the
current study addresses the modulating action of pharmacologic
concentrations of ANF which may not be relevant to physio-
logic concentrations, one may speculate that based upon pre-
vious and present observations, ANF may serve to inhibit TGF
activation both at the single nephron and at the level of the
whole kidney. This action of ANF may be, in part, via a direct
hemodynamic action upon the afferent arteriole which antago-
nizes TGF-mediated decreases in RBF occurring in response to
the generation of metabolically active metabolites of adenosine
stimulated during TGF-activation.
Other pharmacologic agents such as calcium antagonists and
converting enzyme inhibitors may also inhibit TGF-mediated
decreases in renal hemodynamics [18, 19]. Thus, while ANF
may not serve as a lone antagonist to TGF, it may represent an
endogenous circulating inhibitor of TGF in the regulation of
glomerular filtration rate. Indeed, increasing evidence contin-
ues to emerge that in pathophysiologic states of intravascular
volume expansion such as to congestive heart failure with
elevated endogenous atrial peptide, ANF serves to preserve
glomerular filtration rate [20—22].
Others have speculated that in states such as acute tubular
necrosis, enhanced solute delivery to the macula densa may
activate tubuloglomerular feedback which may augment reduc-
tions in GFR [23, 241. Recently, studies have demonstrated a
therapeutic role for pharmacologic concentrations of ANF to
restore GFR in models of acute renal failure [25, 261. While
such actions of ANF at pharmacologic concentrations to re-
store GFR in acute renal failure may represent direct effects
upon glomerular dynamics, an inhibition of TGF could be an
additional mechanism.
In summary, the present findings demonstrate at the whole
kidney level that ANF attenuates HS-induced reductions in
RBF and GFR. This study further demonstrates that ANF also
attenuates adenosine-mediated reductions in GFR. These stud-
ies support a modulating role for pharmacologic concentrations
of ANF in the regulation of RBF and GFR responses to
tubuloglomerular feedback control of renal blood flow and
glomerular filtration.
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